<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> accounts for a great majority of <z:hpo ids='HP_0011420'>deaths</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>According to the World Health Organization, the prevalence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in diabetic patients ranges from 26 to 36% </plain></SENT>
<SENT sid="2" pm="."><plain>Fatality rate after <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> is greater in diabetic patients, and overall prognosis after <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> is worse </plain></SENT>
<SENT sid="3" pm="."><plain>Based on these observations, it has been proposed that <z:mp ids='MP_0002055'>diabetes</z:mp> should be considered as a <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> risk equivalent </plain></SENT>
<SENT sid="4" pm="."><plain>If that is the case, prevention of <z:mp ids='MP_0002055'>diabetes</z:mp> and early intervention should be pursued </plain></SENT>
<SENT sid="5" pm="."><plain>This view is supported by the notion that cardiovascular risk is already increased in people with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, higher-than-optimum blood <z:chebi fb="105" ids="17234">glucose</z:chebi> is a major cause of cardiovascular mortality in most world regions of the world </plain></SENT>
<SENT sid="7" pm="."><plain>Whether dysglycemia is a marker for a more complex metabolic condition or may directly contribute to excess cardiovascular risk is still a matter of debate </plain></SENT>
<SENT sid="8" pm="."><plain>However, experimental work has shown how <z:mp ids='MP_0005559'>increased glucose level</z:mp> can trigger multiple mechanisms of susceptibility to <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, and <z:mp ids='MP_0002055'>diabetes</z:mp> prevention trials have indicated that along with reduction of the rate of conversion toward <z:mp ids='MP_0002055'>diabetes</z:mp>, significant improvement in <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> occurs </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, in the STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp> trial, targeting postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> was associated with reduction in new cases of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and any cardiovascular events </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, dysglycemia should be included in the list of established <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> and early treatment introduced in the attempt to improve <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality </plain></SENT>
</text></document>